


NEWSLETTER

Volume 4, July 2022

Hematology Cancer Consortium (HCC), is a multi-center collaborative academic organization established with the aim to improve knowledge, standardize cost-effective treatment strategies and promote regionally relevant research in hematological cancers.

In this biannual newsletter, we are sharing updates in brief from January - June 2022.

Our 23 Institutional Partners



HCC is deeply grateful to its individual & corporate supporters for their generosity.

YOU CAN JOIN US ON:



ADDITION TO OUR HCC FAMILY

We welcome on board our New Data Entry Operators

OUR NEW DATA ENTRY OPERATORS

Mamatha S E joined as DEO at Ramaiah Medical College Hospital, Bengaluru

Maneesha joined as DEO at Amala Institute of Medical Sciences, Thrissur

Amandeep joined as DEO at Dr. B.R.A Institute Rotary Cancer Hospital, IRCH, AIIMS, Delhi

Antony joined as DEO at Rajagiri Hospital, Kochi

Monicaa joined as DEO at Cancer Institute (WIA), Chennai

Ankit Tiwari joined as DEO at Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow

Maria Salome V joined as DEO at Mazumdar Shaw Medical Center, Narayana Health, Bangalore

ONGOING AND UPCOMING RESEARCH

Ongoing Clinical Trials

Study Title: Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (HCC pRISM-S)

- Duration of study: 5 years
- Date of Study commencement: 1st July 2020
- No of Centres participating in this study: 17
- CTRI Registration No: CTRI/2020/07/026450
- Update: Accrual complete, data analysis ongoing

Study Title: Evaluation of the safety and efficacy of generic low-dose Dasatinib for frontline therapy in chronic-phase chronic myeloid leukemia - A multi-center phase II single-arm study (GLaD Study)

- Duration of Study: 2 years
- Date of Study commencement: October 2020
- No of Centers participating in this study: 11
- CTRI Registration No: CTRI/2020/10/028317
- Update: Accrual is complete. Last patient last follow-up (12-month follow-up) is due by mid of August 2022.

Study Title: COVID-19 Hematological Cancers Registry of India (CHCRI Study)

- Study Design: Observational [Patient Registry]
- Observational Model: Case-Only
- Time Perspective: Prospective and Retrospect
- Actual Study Start Date: 1st November 2020
- Update: Accrual is ongoing. 1330 cases registered.

Study Title: Outcomes and prognostic factors in patients with Burkitt's Lymphoma: Real World Data (BL Study)

- Study design: Observational, retrospective cohort
- Time Perspective: All consecutive patients registered between January 2012 to December 2019
- No of Centers participating in this study: 11
- Update: 9 centers have received approval and have completed data entry to the registry.

Cont..

Ongoing Clinical Trials

Study Title: Epidemiology and treatment outcomes of patients older than 55 years of age with Acute Myeloid Leukemia in India. (HCC Elderly AML)

- Study design: Observational, retrospective cohort
- Time Perspective: All consecutive patients registered between January 2018 to April 2021, based on current WHO criteria
- No of Centers participating in this study: 17
- Update: 8 centers have received IEC approval.

Study Title: Care of patients with Acute Myeloid Leukemia during COVID in India - HCC Leucoin Study

- Study Design: Observational, retrospective comparative analysis of data between two time periods
- Time Perspective: A] 1st January 2018 to 31st March 2020 (pre-COVID-19)
B] 1st April 2020 to 31st August 2021 (COVID-19 era)
- No of Centers participating in this study: 17
- Update: 10 centers have received IEC approval.

Upcoming Clinical Trials

Study Title: Phase III open labeled randomized controlled study to evaluate the optimal dose of all-trans retinoic acid in the treatment of low and intermediate risk acute promyelocytic leukemia. (HCC-APL22 DOSA Study)

- Study design: Phase III open labeled Randomized Control Trial
- Sample size: 280 patients (140 patients in each arm)
- Study duration: 3 years
- Objective: To evaluate the net treatment benefit (event-free survival, documented infections, differentiation syndrome, hepatotoxicity and neuropathy in decreasing order) between the two study arms.
- Indication: Patient newly diagnosed with Acute Promyelocytic Leukemia and age more than 15 years at diagnosis.
- Update: Protocol writing is complete. Designed ICF's and CRF. Site evaluation criteria is ready. Synopsis along with NDA has been shared with the members.

EDUCATION & TRAINING






Nursing Webinars

We are pleased to share that the HCC nurses group had initiated an education program to enhance knowledge.

Fourteen webinars have been conducted so far. Webinars are held on the last Tuesday of every month.

Thank you, team!

Nursing Webinars conducted since January-22:

<p>Topic: Childhood and Young All Sticking to Protocol - A Nursing Perspective</p> <p>Speaker: Capt. Monika, BSC nursing, Diploma in oncology nursing, Hematology day-care and BMT, Command Hospital, Kolkata</p>	
<p>Topic: Childhood and Young All Sticking to Protocol - A Nursing Perspective</p> <p>Speaker: Lt Gunjan Rawat, BSC(Hons) nursing, Hematology day-care and BMT, Command Hospital, Kolkata</p>	
<p>Topic: Role of Nurses in Bone Marrow Transplant</p> <p>Speaker: Sindhu S, BMT In charge, Malabar Cancer Center, Thalassery, Kannur, Kerala</p>	
<p>Topic: PICC insertion care & maintenance</p> <p>Speaker: Jyothi Vidya, Senior Registered Nurse, HCGMSR Cancer hospital, Bangalore</p>	
<p>Topic: Common investigations in Hemato-Oncology (BMT)</p> <p>Speaker: Preethi S, Nursing Officer, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry</p>	

Webinar recordings are available on our website: <http://hemecancer.org/>

Register as a member to access recordings – <http://hemecancer.org/webinar-recording.php>

TRAINING

We encourage our Data Entry Operators to attend various training programs conducted by Hematology Cancer Consortium.

We conducted a special workshop for DEO's on 27th and 28th May 2022 in collaboration with the CDMC team.

Basics about Hematologic cancers	Dr. Manju Sengar
CDMC: Data collection system & Data quality	Dr. Prasanna Samuel
HCC online platform & Pitfalls in data collections with examples	Mr. Omprakash
Overview & explanation of terminologies used in software: APML ALL AML CML Lymphoma	Dr. Has Mukh Jain Dr. Prasanth Ganesan Dr. Manju Sengar Dr. Rajan Kapoor Dr. Anu Korula

DEO workshop training program recordings are now available on the HCC website.

NEW UPDATES & UPCOMINGS

Hematology Cancer Consortium's (HCC) 2nd Annual Meeting in association with Society of Hematologic Oncology (SOHO) is to be held from 21st to 23rd October, 2022 at Rustom Choksi Auditorium, Tata Memorial Hospital, Mumbai.

You can visit the conference website using below link:

<https://hemecancer.org/2022/>

Registration is now open:

<https://icem.eventsair.com/hcc-2022/hcc2022/Site/Register>

INDIVIDUALS AND INSTITUTIONS WITH AN INTEREST IN HEMATOLOGICAL MALIGNANCIES CAN BECOME MEMBERS, REGISTER : [HTTP://HEMECANCER.ORG/MEMBERSHIP.PHP](http://hemecancer.org/membership.php)